LifeMD (NASDAQ:LFMD) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen cut shares of LifeMD (NASDAQ:LFMD) from a hold rating to a sell rating in a report issued on Saturday morning.

Several other research analysts also recently commented on the stock. Weiss Ratings raised shares of LifeMD from a “sell (e+)” rating to a “sell (d)” rating in a report on Thursday, May 7th. BTIG Research reaffirmed a “buy” rating and issued a $10.00 price target on shares of LifeMD in a report on Monday, May 4th. UBS Group reiterated a “buy” rating on shares of LifeMD in a research report on Wednesday, May 27th. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of LifeMD in a research note on Tuesday, May 26th. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $9.14.

LifeMD Price Performance

LFMD opened at $4.15 on Friday. LifeMD has a fifty-two week low of $2.56 and a fifty-two week high of $12.72. The firm has a market capitalization of $200.69 million, a P/E ratio of 83.02 and a beta of 1.99. The company’s 50-day moving average is $4.55 and its 200 day moving average is $3.97.

LifeMD (NASDAQ:LFMD) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.06). The firm had revenue of $50.16 million during the quarter, compared to the consensus estimate of $48.84 million. LifeMD had a negative return on equity of 150.88% and a net margin of 2.37%. On average, equities research analysts expect that LifeMD will post -0.37 earnings per share for the current year.

Institutional Trading of LifeMD

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd purchased a new stake in LifeMD in the fourth quarter worth $36,000. R Squared Ltd purchased a new position in shares of LifeMD in the 1st quarter worth about $41,000. Magnus Financial Group LLC purchased a new stake in LifeMD during the 4th quarter valued at about $41,000. Jain Global LLC bought a new stake in LifeMD during the 4th quarter valued at about $45,000. Finally, Quarry LP bought a new stake in LifeMD during the 3rd quarter valued at about $52,000. Hedge funds and other institutional investors own 35.52% of the company’s stock.

LifeMD Company Profile

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.